Why Khosla’s SVP Won’t Touch China
- Goldman’s Kostin Sees S&P 500 at 4,900 Next Year
- How SVP’s Khosla Built an ‘Edge’ in Distressed Debt
Stories You May Also Like:
Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here’s Why That’s a Smart Move.
Hot off the approval of its gene therapy for a pair of rare hereditary blood disorders, Vertex Pharmaceuticals (VRTX -0.96%)
